

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 13, 2025

PE anti-human/mouse Granzyme B Recombinant

RRID:AB_2687032

Type: Antibody

Proper Citation

(BioLegend Cat# 372208, RRID:AB_2687032)

Antibody Information

URL: http://antibodyregistry.org/AB_2687032

Proper Citation: (BioLegend Cat# 372208, RRID:AB_2687032)

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687032

Vendor: BioLegend

Catalog Number: 372208

Alternative Catalog Numbers: 372207

Record Creation Time: 20231110T034045+0000

Record Last Update: 20240725T041335+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wang Z, et al. (2024) Suppression of the METTL3-m6A-integrin β 1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell reports, 43(2), 113796.

Wang R, et al. (2024) H3K9 lactylation in malignant cells facilitates CD8⁺ T cell dysfunction and poor immunotherapy response. Cell reports, 43(9), 114686.

Wang Q, et al. (2024) Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. Journal of experimental & clinical cancer research : CR, 43(1), 224.

Hu Y, et al. (2024) Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity. Cell reports. Medicine, 5(5), 101530.

Wang X, et al. (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer cell, 42(10), 1729.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. Cell reports, 43(12), 115015.

Zhou W, et al. (2024) Stem-like progenitor and terminally differentiated TFH-like CD4⁺ T cell exhaustion in the tumor microenvironment. Cell reports, 43(2), 113797.

Kloosterman DJ, et al. (2024) Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell, 187(19), 5336.

Guo F, et al. (2024) CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A. Cellular and molecular

life sciences : CMLS, 81(1), 307.

Yang F, et al. (2023) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. *Cell metabolism*, 35(1), 84.

Xiao BL, et al. (2023) HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy. *Cancer immunology research*, 11(2), 228.

Perera DJ, et al. (2023) BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine. *iScience*, 26(9), 107612.

Jiao D, et al. (2023) Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity. *Cell reports*, 42(10), 113211.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. *Med (New York, N.Y.)*, 4(6), 373.

Egan H, et al. (2023) Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. *Cell reports*, 42(5), 112475.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Monteiro de Oliveira Novaes JA, et al. (2021) Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. *Cancer prevention research (Philadelphia, Pa.)*, 14(3), 313.

Rudd CE, et al. (2020) Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. *Cell reports*, 30(7), 2075.

Dong MB, et al. (2019) Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. *Cell*, 178(5), 1189.